Case Study: Targeting BCMA – Multiple Myeloma

Solutions & Cell Therapy Types Accelerated by IsoPlexis

  • Multiple Myeloma

Pre-clinical Choice Metric

Discover the true function of engineered cell products and the functional subsets that make a difference.

View Publication

Research Area

Development Stage

Pre-clinical

Goal

Reveal the most potent candidates in targeting BCMA-Multiple Myeloma

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

Demonstrated the positive association of polyfunctional strength index (PSI) to the functional enhancement of trimeric APRIL (TriPRIL) CAR-T cells1

polyfunctional cell

Finding

The PSI helped correlate uniquely with tumor killing activity against both human cells and mouse models in vitro and in vivo and show improvement difference of TriPRIL CAR-T cells vs. April and conventional BCMA CAR-T cells

follow our data

Follow Our Data

See the latest published data in Cell Therapeutic Discovery Research

Identified highly upregulated polyfunctionality in TriPRIL CAR-T cell products that target both B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI).

View Publication
BCMA polyfunctionality

Solution

Detect Critical Differences

Revealed the superiority of BCMA/TACI-specific polyfunctional response of TriPRIL CAR-T cells to the cell products with a monomeric, APRIL format.

Demonstrated the impact of polyfunctional metrics by single-cell IsoCode chip proteomics in precisely profiling dual-specific TriPRIL CAR-T cells for the prevention and treatment of patients with relapsed/refractory Multiple Myeloma.

View Publication
BCMA Mice

Request a Seminar

Request a Seminar
Discover IsoLight